• Login
    View Item 
    •   DSpace@RPI Home
    • Rensselaer Libraries
    • RPI Theses Open Access
    • View Item
    •   DSpace@RPI Home
    • Rensselaer Libraries
    • RPI Theses Open Access
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Metabolic engineering and applied enzymology for the preparation of nutraceutical/ pharmaceutical chondroitin sulfate

    Author
    He, Wenqin
    Thumbnail
    View/Open
    178241_He_rpi_0185E_11084.pdf (9.769Mb)
    Other Contributors
    Koffas, Mattheos A. G.; Linhardt, Robert J.; Barquera, Blanca L.; Karande, Pankaj;
    Date Issued
    2017-05
    Subject
    Chemical engineering
    Degree
    PhD;
    Terms of Use
    This electronic version is a licensed copy owned by Rensselaer Polytechnic Institute, Troy, NY. Copyright of original work retained by author.;
    Metadata
    Show full item record
    URI
    https://hdl.handle.net/20.500.13015/1963
    Abstract
    Chondroitin sulfate (CS) is an important glycosaminoglycan that is predominantly present in cartilage and the surfaces of many cells and extracellular matrices. It has been widely used in treating osteoarthritis due to its anti-inflammatory and chondroprotective properties. Given the importance of CS in medicine and as a dietary supplement, the traditional animal extraction method which risks virus and/or prion contamination should be replaced by a standardized bioengineering process. The general mechanism of synthesizing CS involves the enzymatic reaction of a membrane-associated sulfotransferase adding sulfo group onto the polymeric chondroitin backbone by adopting a sulfo donor 3'-phosphoadenosine 5'-phosphosulfate (PAPS). The capsular polysaccharide of pathogenic Escherichia coli K4 strain shares a similar structure to the CS precursor, chondroitin. We first overexpressed the genes involved in the biosynthesis of K4 polysaccharide in a non-pathogenic production strain BL21Star™ (DE3).; This strain produced ~2.4g/l chondroitin in DO-STAT fed-batch fermentor. The next challenge is the functional expression of membrane-associated chondroitin sulfotransferase, which typically requires post modification of N-glycosylation site. The recent success of expressing Homo sapiens chondroitin 4-sulfotransferase in BL21Star™ (DE3) by applying several protein engineering strategies enables a high level of conversion of chondroitin to CS type-A in vitro. The next challenge was improving the availability of the sulfur donor PAPS. PAPS is traditionally generated by chemical synthesis, which results in low yield and high cost. To resolve this issue, a simple and efficient enzymatic scheme was utilized by single plasmid system consisting of three related genes expressed in E. coli BL21 Star™ (DE3). With all the efforts, the metabolic engineering approach of chondroitin synthesis, expression of C4ST-1 and enzymatic synthesis of PAPS, will open up a new regime in bioengineering microbial chondroitin sulfate.;
    Description
    May 2017; School of Engineering
    Department
    Dept. of Chemical and Biological Engineering;
    Publisher
    Rensselaer Polytechnic Institute, Troy, NY
    Relationships
    Rensselaer Theses and Dissertations Online Collection;
    Access
    Users may download and share copies with attribution in accordance with a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. No commercial use or derivatives are permitted without the explicit approval of the author.;
    Collections
    • RPI Theses Online (Complete)
    • RPI Theses Open Access

    Browse

    All of DSpace@RPICommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    Login

    DSpace software copyright © 2002-2022  DuraSpace
    Contact Us | Send Feedback
    DSpace Express is a service operated by 
    Atmire NV